Katrin Schlack - Concepedia

Author

Katrin Schlack

University Hospital Münster ORCID

Also Known As

K. Schlack, Katrin Schlack, Schlack, Katrin

109

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

University Hospital Münster Essen University Hospital Heidelberg University University Hospital Heidelberg Heinrich Heine University Düsseldorf

About

Katrin Schlack is an author at University Hospital Münster specializing in medicine, emergency medicine, and sepsis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	60
2	Emergency Medicine	1	1	49
3	Immunology	1	1	11
4	Pathology	1	1	11
5	Cancer Cell Biology	1	1	11

Katrin Schlack

Publications

729

Citations

H-Index

Page 1

	Year	Citations
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis Robert Seifert, Katharina Kessel, Katrin Schlack, European Journal of Nuclear Medicine and Molecular Imaging	2020	140
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Journal of Clinical Oncology	2024	95
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving <sup>177</sup>Lu-PSMA-617 Katharina Kessel, Robert Seifert, Michael Schäfers, Theranostics	2019	79
Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock Sebastian Rehberg, Christian Ertmer, Gabriele Köhler, Intensive Care Medicine Animal PhysiologyArginine VasopressinVeterinary ScienceFirst-line Vasopressor AgentsSepsis	2009	49
Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis Robert Seifert, Katharina Kessel, Katrin Schlack, European Journal of Nuclear Medicine and Molecular Imaging	2020	45
Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort Stefanie Zschäbitz, Nadine Biernath, Thomas Hilser, European Urology Open Science	2023	41
Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy Robert Seifert, Katharina Kessel, Katrin Schlack, Theranostics	2021	40
<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma Niklas Klümper, Damian J. Ralser, Romina Zarbl, Journal for ImmunoTherapy of Cancer	2021	38
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving <sup>177</sup>Lu-PSMA-617 Radioligand Therapy Katharina Kessel, Robert Seifert, Matthias Weckesser, Theranostics	2020	36
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Martin Boegemann, Katrin Schlack, Stefan Thomes, International Journal of Molecular Sciences	2017	34

Page 1